|
Jun 27
|
Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial
|
|
Jun 24
|
Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003
|
|
Jun 16
|
Enveric Biosciences Announces Participation in 2025 BIO International Convention
|
|
Jun 10
|
Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders
|
|
May 28
|
Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003
|
|
Jul 25
|
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
|
|
Jun 25
|
Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
|
|
May 30
|
Enveric Biosciences to Participate in BIO International Convention 2024
|
|
May 15
|
Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
|
|
May 14
|
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
|
|
May 8
|
Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
|
|
Mar 26
|
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
|
|
Mar 19
|
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
|
|
Mar 12
|
Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets
|
|
Dec 29
|
Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market
|
|
Dec 28
|
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series
|
|
Dec 27
|
Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373
|
|
Dec 20
|
Enveric Biosciences to Participate in Biotech Showcase 2024 During "J.P. Morgan Week 2024"
|
|
Dec 5
|
Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds
|
|
Nov 29
|
Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
|